Oculis Holding AG shares plunged >35% after both Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema failed primary ...
European commercialization introduces an additional aflibercept biosimilar option for major retinal indications, potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results